Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

News Briefs

Roche and ICN Settle Patent Dispute over Drug

January 9, 2003

The Roche Group has settled a patent dispute with ICN Pharmaceuticals and its Ribapharm unit over the standard hepatitis therapy ribavirin, clearing the way for Roche to sell a hepatitis drug. The companies gave no financial terms, but said all legal action over ribavirin would stop, and Roche will keep marketing its own branded version, Copegus, worldwide. Roche developed Copegus on its own, but it has the same active ingredient as ribavirin. Ribapharm will license ribavirin to Roche. The agreement permits Roche to sell the hepatitis C drug Pegasys in combination with Copegus.

Back to other CDC news for January 9, 2003

Previous Updates

Adapted from:
New York Times
01.09.03; Reuters



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 

Tools
 

Advertisement